Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d
- PMID: 3033269
- PMCID: PMC254117
- DOI: 10.1128/JVI.61.5.1416-1420.1987
Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d
Abstract
The major Epstein-Barr virus (EBV) envelope glycoprotein, gp350, was purified from the B95-8 cell line and analyzed for its ability to mediate virus attachment to the isolated EBV/C3d receptor (CR2) of human B lymphocytes. Purified gp350 and EBV, but not cytomegalovirus, exhibited dose-dependent binding to purified CR2 in dot blot immunoassays. Binding was inhibited by certain monoclonal antibodies to CR2 and to gp350. Liposomes bearing incorporated gp350 bound to CR2-positive B-cell lines but not to CR2-negative lines. Liposome binding was also inhibited by the OKB7 anti-CR2 monoclonal antibody. A computer-generated comparison of the deduced gp350 amino acid sequence with that of the human C3d complement fragment revealed two regions of significant primary sequence homology, a finding which suggests that a common region on these two unrelated proteins may be involved in CR2 binding.
Similar articles
-
Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).J Biol Chem. 2007 Dec 14;282(50):36614-25. doi: 10.1074/jbc.M706324200. Epub 2007 Oct 9. J Biol Chem. 2007. PMID: 17925391
-
Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.J Immunol. 1986 Jun 1;136(11):4140-5. J Immunol. 1986. PMID: 3009615
-
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.J Biol Chem. 1990 Jul 25;265(21):12293-9. J Biol Chem. 1990. PMID: 1695627
-
CR2 complement receptor.J Invest Dermatol. 1990 Jun;94(6 Suppl):112S-117S. doi: 10.1111/1523-1747.ep12876069. J Invest Dermatol. 1990. PMID: 2161885 Review.
-
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).Adv Immunol. 1989;46:183-219. doi: 10.1016/s0065-2776(08)60654-9. Adv Immunol. 1989. PMID: 2551147 Review. No abstract available.
Cited by
-
The role of virus infections in Sjögren's syndrome.Front Immunol. 2022 Sep 6;13:823659. doi: 10.3389/fimmu.2022.823659. eCollection 2022. Front Immunol. 2022. PMID: 36148238 Free PMC article. Review.
-
The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection.Virology. 2016 Jul;494:23-8. doi: 10.1016/j.virol.2016.04.002. Epub 2016 Apr 8. Virology. 2016. PMID: 27061054 Free PMC article.
-
Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.J Virol. 1991 Jul;65(7):3559-65. doi: 10.1128/JVI.65.7.3559-3565.1991. J Virol. 1991. PMID: 1645784 Free PMC article.
-
Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.Immunol Res. 1999;20(3):187-94. doi: 10.1007/BF02790402. Immunol Res. 1999. PMID: 10741859 Review.
-
Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells.J Virol. 2000 Jul;74(14):6324-32. doi: 10.1128/jvi.74.14.6324-6332.2000. J Virol. 2000. PMID: 10864642 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous